FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Josep Tabernero

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Devices

Drug Delivery Systems

Physiology

Co-author Network

Publications

TOP 3
Rodrigo Dienstmann; Jordi Rodon; Jordi Barretina; Josep Tabernero
Genomic medicine frontier in human solid tumors: prospects and challenges.
Rodrigo Dienstmann; Jordi Rodon; Josep Tabernero
Biomarker-driven patient selection for early clinical trials.
Josep Tabernero; Iva Toudjarska; Akshay K Vaishnaw; Glen J Weiss; Amy C Seila White; Maria Alsina; David Bumcrot; Jeffrey Cehelsky; Andres Cervantes; Daniel C Cho; Valerie A Clausen; Rick Falzone; Christina Gamba-Vitalo; Jared A Gollob; Mrinal M Gounder; Jamie Harrop; Gregory Hinkle; Renta M Hutabarat; Jeffrey R Infante; Patricia M LoRusso; Rachel E Meyers; Saraswathy V Nochur; Luis Paz-Ares; Dinah W Y Sah; Gary K Schwartz; Geoffrey I Shapiro; Nenad Svrzikapa; Howard A Burris
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Josep Tabernero (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Rodrigo Dienstmann; Jordi Rodon; Jordi Barretina; Josep Tabernero
Genomic medicine frontier in human solid tumors: prospects and challenges.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(15):1874-84.
2013: Rodrigo Dienstmann; Jordi Rodon; Josep Tabernero
Biomarker-driven patient selection for early clinical trials.
Current opinion in oncology 2013;25(3):305-12.
2013: Josep Tabernero; Iva Toudjarska; Akshay K Vaishnaw; Glen J Weiss; Amy C Seila White; Maria Alsina; David Bumcrot; Jeffrey Cehelsky; Andres Cervantes; Daniel C Cho; Valerie A Clausen; Rick Falzone; Christina Gamba-Vitalo; Jared A Gollob; Mrinal M Gounder; Jamie Harrop; Gregory Hinkle; Renta M Hutabarat; Jeffrey R Infante; Patricia M LoRusso; Rachel E Meyers; Saraswathy V Nochur; Luis Paz-Ares; Dinah W Y Sah; Gary K Schwartz; Geoffrey I Shapiro; Nenad Svrzikapa; Howard A Burris
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
Cancer discovery 2013;3(4):406-17.
2013: Sun Tian; Laura van't Veer; Rene Bernards; Victor Moreno; Paul Roepman; Ramon Salazar; Iris Simon; Mireille Snel; Josep Tabernero; Gabriel Capella
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Gut 2013;62(4):540-9.
2013: Jordi Rodon; Violeta Serra; Rodrigo Dienstmann; Josep Tabernero
Development of PI3K inhibitors: lessons learned from early clinical trials.
Nature reviews. Clinical oncology 2013;10(3):143-53.
2012: Leticia De Mattos-Arruda; Joan Seoane; Josep Tabernero; Javier Cortes
Circulating tumour cells in early breast cancer.
The lancet oncology 2012;13(9):e370; author reply e370.
2012: Andres Cervantes; Jeffrey Ecsedy; Elena Elez; Howard Fingert; Jungah Jung; Teresa Macarulla; Laura Maños; José-Alejandro Pérez-Fidalgo; Adelaida Piera; Desamparados Roda; Susana Roselló; Juan Manuel Sanchis-Garcia; Jordi Andreu; Jose Baselga; Inma Blasco; Karthik Venkatakrishnan; Josep Tabernero
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4764-74.
2012: Rodrigo Dienstmann; Elena Elez; Javier Hernandez Losa; Stefania Landolfi; Teresa Macarulla; Jose Perez-Garcia; Ludmila Prudkin; Jordi Rodon; Gessamí Sánchez-Ollé; Cristina Saura; Danila Serpico; Maria Alsina; Claudia Aura; Jaume Capdevila; Ana Vivancos; Josep Tabernero
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
Molecular cancer therapeutics 2012;11(9):2062-71.
2012: B Markman; M Melendez Cuero; M Mita; G I Shapiro; Lillian Siu; S Stutvoet; Josep Tabernero; Diana Birle; L C Chen; W Hackl; I Krop; O Anak; José Baselga
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(9):2399-408.
2012: Stephan P Tenbaum; Ana Vivancos; Isabel Puig; Santiago Ramón y Cajal; Santiago Rojas; Simó Schwartz; Josep Tabernero; Susana Aguilar; Oriol Arqués; José Baselga; Irene Chicote; Eloi Espín; Yolanda Fernández; Gispert Juan; Jose R Herance; Stefania Landolfi; Leire Mendizabal; Alberto Muñoz; Paloma Ordóñez-Morán; Héctor G Palmer
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
Nature medicine 2012;18(6):892-901.
2012: Jordi Rodón; Cristina Saura; José Baselga; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; Josep Tabernero
Molecular prescreening to select patient population in early clinical trials.
Nature reviews. Clinical oncology 2012;9(6):359-66.
2012: Rodrigo Dienstmann; Ben Markman; Josep Tabernero
Application of monoclonal antibodies as cancer therapy in solid tumors.
Current clinical pharmacology 2012;7(2):137-45.
2012: Guillem Argiles; Rodrigo Dienstmann; Elena Elez; Josep Tabernero
Panitumumab: a summary of clinical development in colorectal cancer and future directions.
Future oncology (London, England) 2012;8(4):373-89.
2012: Jaume Capdevila; Jesús Corral; Enrique Grande; Juan Jose Grau; Irene Halperin; Lara Iglesias; Javier Martínez-Trufero; Gabriel Obiols; Angel Segura; Maria Ángeles Vaz; Josep Tabernero
Sorafenib in metastatic thyroid cancer.
Endocrine-related cancer 2012;19(2):209-16.
2012: C Serrano; Josep Tabernero; M Vidal; José Baselga; M Bellet; M J Carreras; J Cortés; L De Mattos-Arruda; P Gómez; E Muñoz-Couselo; J Pérez; G Sánchez-Ollé; Cristina Saura; S Di Cosimo
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(4):897-902.
2012: Rodrigo Dienstmann; Enriqueta Felip; Sara De Dosso; Josep Tabernero
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
Molecular oncology 2012;6(1):15-26.
2012: Rocco Mazzolini; Mark S Mooseker; Santiago Ramón y Cajal; Paulo Rodrigues; Simo Schwartz; Josep Tabernero; Lauri A Aaltonen; Hafid Alazzouzi; Pia Alhopuro; Elena Andretta; Manel Armengol; Sarah Bazzocco; Wakam Chang; Higinio Dopeso; Eloy Espín; Johannes Gebert; Javier Hernandez Losa; Matthias Kloor; Stefania Landolfi; John M Mariadason; Silvia Mateo-Lozano; Diego Arango
Brush border myosin Ia has tumor suppressor activity in the intestine.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(5):1530-5.
2011: Leticia De Mattos-Arruda; David Olmos; Josep Tabernero
Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer.
Future oncology (London, England) 2011;7(12):1385-97.
2011: Leticia De Mattos-Arruda; Rodrigo Dienstmann; Josep Tabernero
Development of molecular biomarkers in individualized treatment of colorectal cancer.
Clinical colorectal cancer 2011;10(4):279-89.
2011: Luis G Paz-Ares; Desamparados Roda; Fiona Russell-Yarde; Jean-Charles Soria; Pablo Umana; José Baselga; Yann Bergé; Andres Cervantes; Jesus Corral; Jean-Pierre Delord; Carlos Gomez-Roca; Simon Hollingsworth; Luigi Manenti; Ben Markman; Josep Tabernero
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(28):3783-90.
2011: Jaume Capdevila; Josep Tabernero
A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Cancer discovery 2011;1(3):213-21.
2011: Eric Van Cutsem; C Van de Velde; N Arber; Y Bang; A Benson; A Cervantes; E Diaz-Rubio; Mario Dicato; M Ducreux; R Geva; R Glynne-Jones; A Grothey; D Haller; Karin Haustermans; Y K Kang; D Kerr; Roberto Labianca; Florian Lordick; J Marshall; B Minsky; Bernard Nordlinger; A Ohtsu; N Pavlidis; A Roth; Philippe Rougier; HJ Schmoll; Alberto Sobrero; Josep Tabernero; J Zalcberg
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22 Suppl 5():v1-9.
2011: Rodrigo Dienstmann; Jordi Rodon; Ben Markman; Josep Tabernero
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.
Recent patents on anti-cancer drug discovery 2011;6(2):210-36.
2011: Rodrigo Dienstmann; Josep Tabernero
BRAF as a target for cancer therapy.
Anti-cancer agents in medicinal chemistry 2011;11(3):285-95.
2011: Fernando Rivera; Maica Galán; Josep Tabernero; Andrés Cervantes; Maria Eugenia Vega-Villegas; Javier Gallego; Berta Laquente; Edith Rodríguez; Alfredo Carrato; Pilar Escudero; Bartomeu Massutí; Vicente Alonso-Orduña; Adelaida Cardenal; Alberto Sáenz; Jordi Giralt; Ana Lucia Yuste; Antonio Antón; Enrique Aranda
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Cancer chemotherapy and pharmacology 2011;67(1):75-82.
2010: Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4697-705.
2010: I Brana; Josep Tabernero
Cardiotoxicity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 7():vii173-9.
2010: Teresa Macarulla; Andres Cervantes; Elena Elez; Edith Rodríguez-Braun; José Baselga; Susana Roselló; Gemma Sala; Inma Blasco; Hadi Danaee; Yih Lee; Jeffrey Ecsedy; Vaishali Shinde; Arijit Chakravarty; Douglas Bowman; Hua Liu; Omar Eton; Howard Fingert; Josep Tabernero
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.
Molecular cancer therapeutics 2010;9(10):2844-52.
2010: Ben Markman; Josep Tabernero
Monoclonal antibodies in solid tumours.
Current clinical pharmacology 2010;5(3):160-5.
2010: Josep Tabernero; F Ciardiello; F Rivera; E Rodriguez-Braun; F J Ramos; E Martinelli; M E Vega-Villegas; S Roselló; S Liebscher; O Kisker; T Macarulla; José Baselga; A Cervantes
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(7):1537-45.
2010: Eric Van Cutsem; Mario Dicato; N Arber; J Berlin; A Cervantes; Fortunato Ciardiello; A De Gramont; E Diaz-Rubio; M Ducreux; R Geva; Bengt Glimelius; R Glynne Jones; A Grothey; T Gruenberger; D Haller; Karin Haustermans; Roberto Labianca; H J Lenz; B Minsky; Bernard Nordlinger; A Ohtsu; N Pavlidis; Philippe Rougier; W Schmiegel; C Van de Velde; HJ Schmoll; Alberto Sobrero; Josep Tabernero
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 6():vi1-10.
2010: César Serrano; Ben Markman; Josep Tabernero
Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
Cancer journal (Sudbury, Mass.) 2010;16(3):226-34.
2010: Higinio Dopeso; Silvia Mateo-Lozano; Elena Elez; Stefania Landolfi; Francisco Javier Ramos Pascual; Javier Hernandez Losa; Rocco Mazzolini; Paulo Rodrigues; Sarah Bazzocco; Maria Josep Carreras; Eloi Espín; Manel Armengol; Andrew J Wilson; John M Mariadason; Santiago Ramon Y Cajal; Josep Tabernero; Simo Schwartz; Diego Arango
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(8):2375-82.
2010: B Markman; F Atzori; J Pérez-García; Josep Tabernero; José Baselga
Status of PI3K inhibition and biomarker development in cancer therapeutics.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(4):683-91.
2010: Josep Tabernero; Andres Cervantes; Fernando Rivera; Erika Martinelli; Federico Rojo; Anja von Heydebreck; Teresa Macarulla; Edith Rodriguez-Braun; Maria Eugenia Vega-Villegas; Stefanie Senger; Francisco Javier Ramos; Susana Roselló; Ilhan Celik; Christopher Stroh; José Baselga; Fortunato Ciardiello
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(7):1181-9.
2010: Jaume Capdevila; Guillem Argiles; Victor Rodriguez-Frexinos; Isaac Nuñez; Josep Tabernero
New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
Discovery medicine 2010;9(45):153-62.
2010: Elena Elez; Maria Alsina; Josep Tabernero
Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status.
Cancer treatment reviews 2010;36 Suppl 1():S15-6.
2010: Ben Markman; Francisco Javier Ramos; Jaume Capdevila; Josep Tabernero
EGFR and KRAS in colorectal cancer.
Advances in clinical chemistry 2010;51():71-119.
2009: Jaume Capdevila; Jose Perez-Garcia; Gabriel Obiols; Josep Tabernero
Targeted therapies in thyroid cancer.
Targeted oncology 2009;4(4):275-85.
2009: Fernando Rivera; Maica Galán; Josep Tabernero; Andrés Cervantes; M Eugenia Vega Villegas; Javier Gallego; Berta Laquente; Edith Rodríguez; Alfredo Carrato; Pilar Escudero; Bartomeu Massutí; Vicente Alonso-Orduña; Adelaida Cardenal; Alberto Sáenz; Jordi Giralt; Ana L Yuste; Antonio Antón; Enrique Aranda
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
International journal of radiation oncology, biology, physics 2009;75(5):1430-6.
2009: Ben Markman; Jaume Capdevila; Elena Elez; Josep Tabernero
New trends in epidermal growth factor receptor-directed monoclonal antibodies.
Immunotherapy 2009;1(6):965-82.
2009: Teresa Macarulla; Jaume Capdevila; José Perez-Garcia; Francisco Javier Ramos; Maria Elena Elez; Ben Markman; Manuel Ruiz-Echarri; Josep Tabernero
New approaches and targets in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():79-88.
2009: Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto Sobrero; Enrico Mini; richard greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; D Cunningham
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3117-25.
2009: Jaume Capdevila; Francisco Javier Ramos; Teresa Macarulla; Elena Elez; Manuel Ruiz-Echarri; Jose Perez-Garcia; Josep Tabernero
Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.
Current opinion in oncology 2009;21(4):374-80.
2009: Jaume Capdevila; Francisco Javier Ramos; Teresa Macarulla; Elena Elez; Josep Tabernero
The role of salvage treatment in advanced colorectal cancer.
Critical reviews in oncology/hematology 2009;71(1):53-61.
2009: Chris Verslype; Eric Van Cutsem; Mario Dicato; N Arber; J D Berlin; D Cunningham; A De Gramont; E Diaz-Rubio; M Ducreux; T Gruenberger; D Haller; Karin Haustermans; P Hoff; D Kerr; R Labianca; M Moore; Bernard Nordlinger; A Ohtsu; Philippe Rougier; W Scheithauer; HJ Schmoll; Alberto Sobrero; Josep Tabernero; C van de Velde
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 7():vii1-vii6.
2009: Jaume Capdevila; Elena Elez; Teresa Macarulla; Francisco Javier Ramos; Manuel Ruiz-Echarri; Josep Tabernero
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.
Cancer treatment reviews 2009;35(4):354-63.
2009: Javier Sastre; Enrique Aranda; Bartomeu Massutí; Josep Tabernero; Manuel Chaves; Albert Abad; Alfredo Carrato; Juan José Reina; Bernardo Queralt; Auxiliadora Gómez España; Encarnación González-Flores; Fernando Rivera; Ferrán Losa; Teresa García; Pedro Sanchez-Rovira; Inmaculada Maestu; Eduardo Díaz-Rubio
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
Critical reviews in oncology/hematology 2009;70(2):134-44.
2008: Francisco Javier Ramos; Teresa Macarulla; Jaume Capdevila; Elena Elez; Josep Tabernero
Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Clinical colorectal cancer 2008;7 Suppl 2():S52-7.
2008: Teresa Macarulla; Francisco Javier Ramos; Elena Elez; Jaume Capdevila; Sergio Peralta; Josep Tabernero
Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.
Clinical colorectal cancer 2008;7(5):300-8.
2008: E Elez; Teresa Macarulla; Josep Tabernero
Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 7():vii146-52.
2008: Jaume Capdevila; Elena Elez; Sergio Peralta; Teresa Macarulla; Francisco Javier Ramos; Josep Tabernero
Oxaliplatin-based chemotherapy in the management of colorectal cancer.
Expert review of anticancer therapy 2008;8(8):1223-36.
2008: Eric Van Cutsem; Mario Dicato; Karin Haustermans; N Arber; J-F Bosset; D Cunningham; A De Gramont; E Diaz-Rubio; M Ducreux; Richard M Goldberg; R Glynne-Jones; D Haller; Y-K Kang; D Kerr; R Labianca; B Minsky; M Moore; Bernard Nordlinger; Philippe Rougier; W Scheithauer; HJ Schmoll; Alberto Sobrero; Josep Tabernero; M Tempero; C Van de Velde; J Zalcberg
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 6():vi1-8.
2008: Francisco Javier Ramos; Josep Tabernero
K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer.
Biomarkers in medicine 2008;2(2):97-9.
2008: Josep Tabernero; Federico Rojo; Emiliano Calvo; Howard Burris; Ian Judson; Katharine Hazell; Erika Martinelli; Santiago Ramon Y Cajal; Suzanne Jones; Laura Vidal; Nicholas Shand; Teresa Macarulla; Francisco Javier Ramos; Sasa Dimitrijevic; Ulrike Zoellner; Pui Tang; Michael Stumm; Heidi A Lane; David Lebwohl; José Baselga
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1603-10.
2008: Beatriz Pardo; Luis Paz-Ares; Josep Tabernero; Eva Ciruelos; Margarita García; Ramón Salazar; Ana López; María Blanco; Antonio Nieto; José Jimeno; Miguel Angel Izquierdo; José M Trigo
Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(4):1116-23.
2008: Josep Tabernero; Per Pfeiffer; Andrés Cervantes
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
The oncologist 2008;13(2):113-9.
2008: Gunnar Folprecht; Josep Tabernero; Claus-Henning Köhne; Charles Zacharchuk; Luis Paz-Ares; Federico Rojo; Susan Quinn; Esther Casado; Ramon Salazar; Richat Abbas; Chantal Lejeune; Irene Marimón; Jordi Andreu; Ulrike Ubbelohde; Hernan Cortes-Funes; Jose Baselga
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):215-23.
2007: Francisco Javier Ramos; Josep Tabernero
Cetuximab and chemotherapy for patients with unresectable CRC liver metastasis: are we changing the natural course of the disease?
Onkologie 2007;30(12):602-4.
2007: Jaume Capdevila; Cristina Saura; Teresa Macarulla; Esther Casado; Francisco Javier Ramos; Josep Tabernero
Monoclonal antibodies in the treatment of advanced colorectal cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007;33 Suppl 2():S24-34.
2007: Josep Tabernero; Eric Van Cutsem; Eduardo Díaz-Rubio; Andrés Cervantes; Yves Humblet; Thierry André; Jean-Luc Van Laethem; Patrick Soulié; Esther Casado; Chris Verslype; Javier Sastre Valera; Giampaolo Tortora; Fortunato Ciardiello; Oliver Kisker; Aimery de Gramont
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5225-32.
2007: Eduardo Díaz-Rubio; Josep Tabernero; Auxiliadora Gómez España; Bartomeu Massutí; Javier Sastre; Manuel Chaves; Albert Abad; Alfredo Carrato; Bernardo Queralt; Juan José Reina; Joan Maurel; Encarnación González-Flores; Jorge Aparicio; Fernando Rivera; Ferrán Losa; Enrique Aranda
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4224-30.
2007: Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; FELICE GIULIANTE; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
European journal of cancer (Oxford, England : 1990) 2007;43(14):2037-45.
2007: I Durán; Ramón Salazar; O Casanovas; V Arrazubi; Eduardo Vilar; Lillian L Siu; J Yao; Josep Tabernero
New drug development in digestive neuroendocrine tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(8):1307-13.
2007: Jaume Capdevila; Guillermo Mendez; Teresa Macarulla; Francisco Javier Ramos; Esther Casado; Josep Tabernero
New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era.
Expert review of anticancer therapy 2007;7(7):1027-41.
2007: Eduardo Vilar; Ramón Salazar; Jose Pérez-García; Javier Cortes; Kjell Oberg; Josep Tabernero
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.
Endocrine-related cancer 2007;14(2):221-32.
2007: Chris Verslype; Eric Van Cutsem; Mario Dicato; S Cascinu; D Cunningham; E Diaz-Rubio; Bengt Glimelius; D Haller; Karin Haustermans; V Heinemann; P Hoff; P G Johnston; D Kerr; R Labianca; C Louvet; B Minsky; M Moore; Bernard Nordlinger; S Pedrazzoli; A Roth; M Rothenberg; Philippe Rougier; HJ Schmoll; Josep Tabernero; M Tempero; C van de Velde; Jean-Luc Van Laethem; J Zalcberg
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 7():vii1-vii10.
2007: Luis Paz-Ares; Fernando Rivera-Herreros; Eduardo Díaz-Rubio; Margarita García; Esther Casado; Ricardo Cubedo; Cristina Gravalos; Vicente Alfaro; Javier Gómez; Miguel Angel Izquierdo; Josep Tabernero
Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.
Clinical colorectal cancer 2007;6(7):522-8.
2007: Josep Tabernero
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Molecular cancer research : MCR 2007;5(3):203-20.
2006: Teresa Macarulla; Francisco Javier Ramos; Jaume Capdevila; Cristina Saura; Josep Tabernero
Novel targets for anticancer treatment development in colorectal cancer.
Clinical colorectal cancer 2006;6(4):265-72.
2006: Federico Rojo; Josep Tabernero; Joan Albanell; Eric Van Cutsem; Atsushi Ohtsu; Toshihiko Doi; Wasaburo Koizumi; Kuniaki Shirao; Hiroya Takiuchi; Santiago Ramon Y Cajal; S Ramon Cajal; José Baselga
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4309-16.
2006: Claudia María Valverde; Teresa Macarulla; Esther Casado; Francisco Javier Ramos; Erika Martinelli; Josep Tabernero
Novel targets in gastric and esophageal cancer.
Critical reviews in oncology/hematology 2006;59(2):128-38.
2006: Eric Van Cutsem; Mario Dicato; N Arber; A Benson; D Cunningham; E Diaz-Rubio; Bengt Glimelius; Richard M Goldberg; D Haller; Karin Haustermans; Y Koo-Kang; R Labianca; I Lang; B Minsky; Bernard Nordlinger; A Roth; Philippe Rougier; HJ Schmoll; Alberto Sobrero; Josep Tabernero; A Szawlowski; C van de Velde
The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 6():vi13-8.
2006: Thierry André; Daniel Sargent; Josep Tabernero; Michael O'Connell; Marc Buyse; Alberto Sobrero; Jean-Louis Misset; Corrado Boni; Aimery de Gramont
Current issues in adjuvant treatment of stage II colon cancer.
Annals of surgical oncology 2006;13(6):887-98.
2006: Teresa Macarulla; Esther Casado; Francisco Javier Ramos; Claudia Valverde; Josep Tabernero
Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.
Onkologie 2006;29(3):99-105.
2005: Josep Tabernero; Teresa Macarulla; Francisco Javier Ramos; J Baselga
Novel targeted therapies in the treatment of gastric and esophageal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(11):1740-8.
2005: Josep Tabernero; Stan Kaye
[Value of inhibition of signal transduction and epigenetic therapy concepts in cancer therapy].
Onkologie 2005;28 Suppl 4():43-7.
2005: Josep Tabernero; Teresa Macarulla
Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities.
Onkologie 2005;28(10):467-70.
2005: José Baselga; Joan Albanell; Amparo Ruiz; Ana Lluch; Pere Gascón; Vicente Guillém; Sonia González; Silvia Sauleda; Irene Marimón; Josep Tabernero; Maria T Koehler; Federico Rojo
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5323-33.
2005: Eduardo Vilar; Josep Tabernero; Esther Casado; Teresa Macarulla; Francisco Javier Ramos; Erika Martinelli; Cristina Saura
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.
American journal of clinical oncology 2005;28(4):424.
2005: Siegfried Segaert; Josep Tabernero; Olivier Chosidow; Thomas Dirschka; Joern Elsner; Luca Mancini; Tim Maughan; Jean-Fran Ois Morere; Armando Santoro; Alberto Sobrero; Eric Van Cutsem; Alison Layton
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2005;3(8):599-606.
2005: Chris J Twelves; Charles A Butts; Jim Cassidy; Thierry Conroy; Fillippo de Braud; Eduardo Diaz-Rubio; Josep Tabernero; Patrick Schoffski; Arie Figer; Rene Brunet; Johannes Grossmann; Alberto Sobrero; Eric Van Cutsem
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Clinical colorectal cancer 2005;5(2):101-7.
2005: Josep Tabernero; Federico Rojo; Irene Marimón; Maurizio Voi; Joan Albanell; Marta Guix; Federico Vázquez; Joan Carulla; Michael Cooper; Jordi Andreu; Anne Van Vreckem; Joaquim Bellmunt; swam manne; James A Manning; Carmen Garrido; Enriqueta Felip; Josep Maria Del Campo; Mónica García; Sonia Valverde; José Baselga
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2521-33.
2005: A Hidalgo; Josep Tabernero; Federico Rojo; I Marimon; Jordi Andreu; José Baselga
Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs.
Abdominal imaging 2005;30(1):65-8.
2004: Josep Tabernero; Miguel Angel Climent; Ana Lluch; Joan Albanell; J B Vermorken; Agustí Barnadas; Antonio Antón; C Laurent; José I Mayordomo; N Estaun; I Losa; Vicente Guillem; Javier Garcia-Conde; J L Tisaire; José Baselga
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(9):1358-65.
2004: Jim Cassidy; Josep Tabernero; Chris Twelves; René Brunet; Charles Butts; Thierry Conroy; Filippo Debraud; Arie Figer; Johannes Grossmann; Noriaki Sawada; Patrick Schöffski; Alberto Sobrero; Eric Van Cutsem; Eduardo Díaz-Rubio
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2084-91.
2004: Josep Tabernero; Ramón Salazar; Esther Casado; E Martinelli; P Gómez; José Baselga
Targeted therapy in advanced colon cancer: the role of new therapies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv55-62.
2004: Josep Tabernero; Luis Paz-Ares; Ramon Salazar; Pilar Lianes; José Guerra; Joan Borrás; Humberto Villavicencio; Oscar Leiva; Hernán Cortés-Funes
Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature.
The Journal of urology 2004;171(1):164-7.
2003: Joaquim Bellmunt; R de Wit; Santiago Albiol; Josep Tabernero; Joan Albanell; José Baselga
New drugs and new approaches in metastatic bladder cancer.
Critical reviews in oncology/hematology 2003;47(2):195-206.
2003: Luis Paz-Ares; Susana Bezares; Josep Tabernero; Daniel Castellanos; Hernán Cortes-Funes
Review of a promising new agent--pemetrexed disodium.
Cancer 2003;97(8 Suppl):2056-63.
2000: Joaquim Bellmunt; Vicente Guillem; Luis Paz-Ares; José Luis González-Larriba; Joan Carles; Joan Albanell; Josep Tabernero; Hernán Cortés-Funes; José Baselga
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
European journal of cancer (Oxford, England : 1990) 2000;36 Suppl 2():17-25.
2000: José M Trigo; Josep Tabernero; Luis Paz-Ares; J L García-Llano; J Mora; Pilar Lianes; E Esteban; R Salazar; J J López-López; Hernán Cortés-Funes
Tumor markers at the time of recurrence in patients with germ cell tumors.
Cancer 2000;88(1):162-8.
1999: Josep Ramón Germà-Lluch; Xavier Garcia del Muro; Josep Tabernero; Miguel Sánchez; Jorge Aparicio; Emilio Alba; Agustí Barnadas
BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG)
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(3):289-93.
1998: Enrique Aranda; Eduardo Díaz-Rubio; A Cervantes; A Antón-Torres; Alfredo Carrato; T Massutí; Josep Tabernero; Javier Sastre; A Trés; Jorge Aparicio; J M López-Vega; Isidoro Barneto; J García-Conde
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):727-31.
1998: Joan Carles; Montserrat Domenech; Antoni Gelabert-Mas; M Nogue; Josep Tabernero; Angels Arcusa; Inmaculada Guasch; A Miguel; J J Ballesteros; Xavier Fabregat
Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
Acta oncologica (Stockholm, Sweden) 1998;37(2):187-91.
1997: Manuel Hidalgo; Luis Paz-Ares; F Rivera; Pilar Lianes; G Huidobro; A Ruiz; M López-Brea; J Sanz-Ortiz; J López López; Hernán Cortés-Funes; Josep Tabernero
Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(6):555-9.
1997: Pablo Maroto; Josep Tabernero; Humberto Villavicencio; R Mesía; Eugenio Marcuello; F J Solé-Balcells; C Sola; J Mora; Ferran Algaba; C Pérez; Xavier León; Juan José López López
Growing teratoma syndrome: experience of a single institution.
European urology 1997;32(3):305-9.